NFL Biosciences: Invest Securities reduces its target

(CercleFinance.com) - Invest Securities confirms its Buy rating on NFL Biosciences shares, with a slightly reduced price target from 8.
8 to 8.5 euros following the termination of the partnership with Themis in India.

"We are updating our model following the publication of H1 results, which highlighted a much lower cost structure", says the analyst.

These should increase slightly in H2 with the preparation of phase III on NFL-101, but we are lowering our expenses significantly for H2 and 2025 to better reflect this limited fixed cost structure", adds the broker.

Invest Securities believes that one or more licensing agreements could be announced by the company before financial resources run out in Q3 25, although the option of carrying out part of the Phase III program itself is not out of the question.


Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as decision-making aids for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.